[Efficacy and safety of cefixim and ciprofloxacin in acute cystitis (a multicenter randomized trial)].

Abstract

A prospective multicenter randomized trial enrolled 104 females aged 18-55 years with acute un-complicated cystitis. The patients were randomized into two groups: 49 patients of group 1 received cefixim in a single dose 400 mg/day for 5 days; 55 patients of group 2 were given ciprofloxacin in a dose 250-500 mg twice a day for 5 days. Clinical and microbiological assessment of efficacy and safety was made before treatment and on treatment day 8 and 28. Significant differences were found between groups 1 and 2 in parameters of bacteriological and clinical efficacy. Eradication of the agent and persistent bacteriological response was seen in 95.9 and 100% patients of group 1, 66 and 100% patients of group 2, respectively. Complete and partial response was observed in 55.1 and 75.5% patients of group 1, 37.3 and 58.1% patients of group 2, respectively. Thus, cefixim in a single dose 400 mg/day for 5 days has a higher microbiological efficacy than ciprofloxacin in a dose 250-500 mg twice a day. Side effects occurred less frequently in the treatment with cefixim.

• Authors: V V Galkin, I V Malev, E V Dovgan', S N Kozlov, V V Rafal'skiĭ
• Journal: Urologiia (Moscow, Russia : 1999) (Urologiia) 2011 Jan-Feb Issue 1 Pg. 13-6 ISSN: 1728-2985 [Print] Russia (Federation)
• PMID: 21504072 (Publication Type: English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Ciprofloxacin
• Cefixime

Topics

• Acute Disease
• Adolescent
• Adult
• Anti-Bacterial Agents (administration & dosage, adverse effects, therapeutic use)
• Cefixime (administration & dosage, adverse effects, therapeutic use)
• Ciprofloxacin (administration & dosage, adverse effects, therapeutic use)
• Cystitis (drug therapy, microbiology)
• Female
• Humans
• Middle Aged
• Prospective Studies
• Treatment Outcome
• Young Adult